Results 201 to 210 of about 53,609 (266)

Functional properties of skeletal myotube-derived extracellular vesicles based on microRNA profiles: a comparative analysis with mesenchymal stem cell-derived extracellular vesicles. [PDF]

Sci Rep
Kawamoto Y, Yamaguchi A, Ma X, Fu Y, Guo Q, Uemura M, Fujino H, Maeshige N.   +7 more
europepmc   +1 more source

Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation. [PDF]

Adv Sci (Weinh)
Lin Z, Yao M, Xu X, Zhang D, Xu L, Rong L, Wang X, Duan Y, Chen C, Gu J, Zhang Y, Liu Q, Ye Q, Cui G, Hao Y, Ma X.   +15 more
europepmc   +1 more source

Increased EGFR/HER2 Pathway Activation Contributes to Skin Tumorigenesis in <i>Tpl2</i>^-^/- Mice. [PDF]

Cancers (Basel)
Purkey LR, Mehedincu S, Irvine C, Akdag R, Little M, Kothmann WW, Rus K, Greenberg E, Shady N, DeCicco-Skinner K.   +9 more
europepmc   +1 more source

Single-cell profiling of ERBB family receptors identifies ERBB3 as a key regulator in head and neck squamous cell carcinoma progression. [PDF]

Discov Oncol
Luo Y, Li Y, Liu S, Hu R, Wu J.
europepmc   +1 more source

Strategic risk assessment in oncology: Utilizing single-agent activity to boost combination therapy approvals. [PDF]

Contemp Clin Trials Commun
Kasim A, Anastasiou M, Loizou E, Dimakakos A, Georganaki M, Mourelatos I, Karelis P, Esposito M, Zhou H, Chen TT, Skaltsas D, Stockman P.   +11 more
europepmc   +1 more source

c-erbB-2 and human cancer.

Japanese journal of cancer research : Gann, 1993
openaire   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway. [PDF]

Cell Death Dis
Li C, Shi S, Li L, Wang Y, Yao M, Yu C, Yu C, Xie C.   +7 more
europepmc   +1 more source

위암에서 c-erbB-2 암유전자 발현에 관한 연구 [PDF]

, 1993
양대현, 유종선, 윤종만, 박창수, 정상우   +4 more
openalex  

表在性膀胱癌における Malignant potential の指標としての ABH-isoantigen -PCNA, c-erbB-2 との関連について [PDF]

, 1994
郭, 春鋼
core